2026-05-10T12:30:12.295Z http://ezaposleni.singidunum.ac.rs/rest/sciNaucniRezultati/oai

ezaposleni.singidunum.ac.rs/rest/sciNaucniRezultati/oai:2:7240 2024-06-29T21:34:54Z 2

Urinary excretion studies of meldonium after multidose parenteral application 2018 http://ezaposleni.singidunum.ac.rs/rest/sciNaucniRezultati/oai/record/2/7240 G. Forsdahla B. Jancic Stojanovic M. Andjelkovic N. Dikić T. Geisendorfer V. Jeitler G. Gmeiner tMeldonium is a drug exhibiting cardioprotective and anti-ischemic effects. Due to its potentialperformance-enhancing benefit in sports, meldonium was added to the World Anti-Doping Agency list ofprohibited substances in 2016. Since then, a high number of adverse analytical findings reported on mel-donium has questioned meldonium‘s detection time in urine. Hence, the objective of the current studywas to characterize the pharmacokinetic urinary excretion pattern of meldonium when administered asmultiple intravenous injections. Three injections of 250 mg meldonium were given over a time periodof five days to six healthy volunteers and urine samples were collected for eight months after the lastinjection of the drug. For the quantification of meldonium in urine, a liquid chromatography-tandemmass spectrometry method was fully validated according to the World Anti-Doping Agency guidelinesin terms of specificity, matrix interferences, intra- and inter-day precision, accuracy, carry-over, robust-ness, linearity, limit of detection, and limit of quantification. The assay was successfully applied to thepharmacokinetic study. A three-compartment model was found to best describe the pharmacokineticsof meldonium with average alpha, beta, and gamma half-lives of 1.4 h, 9.4 h, and 655 h, respectively. Thedetection time in urine varied between 94 and 162 days. article 161 289 295 0731-7085 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS